氟卡胺治疗难治性阵发性心房纤颤疗效观察

Flecainide in drug resistant paroxysmal atrial fibrillation

本文报道用氟卡胺治疗一组奎尼丁、胺碘酮等耐药性阵发性心房纤颤（ＰＡＦ）患者。结果显示，９４％的患者其ＰＡＦ完全或部分消失，迷走神经诱发的ＰＡＦ疗效似更好，患者对氟卡胺的耐受性良好，亦未发现致心律失常作用。结合文献考虑，认为可推荐氟卡胺作为ＰＡＦ的首选治疗药。

Flecainide was used for prevention of paroxysmal atrial fibrillation (PAF) in 18 patients with frequent symptomatic attacks that were resistant or intolerant to quinidine,amiodarone,and so on.Vagally induced PAF was clinically documented in 12 patients.After 3￣24 monthes of follow up,complete or partial disappearance of PAF was observed in 17 patients (94%).The success rate seems slightly higher in patients with vagally induced PAF.The patients were well tolerated to flecainide.No prearrhythmias effects were detected.No death occurred during the follow up.It could be concluded that flecainide may be a first choice drug in treatment of PAF.